Biden had not received prostate cancer screening since 2014, spokesperson says

Former U.S. President Joe Biden was diagnosed with advanced prostate cancer last week, raising questions about the lack of PSA testing in the decade prior to the diagnosis; his last known test was in 2014. A spokesperson noted that Biden had never been diagnosed with prostate cancer prior to Friday. While some health professionals expressed surprise given routine health monitoring for presidents, others noted that discontinuing PSA testing in older patients is not unusual due to its decreased reliability, a practice supported by a 2017 U.S. Preventive Services Task Force recommendation against screening men over 70.

Analysis

Former U.S. President Joe Biden, 82, has been diagnosed with an advanced, stage 4 prostate cancer that has metastasized to his bones, a development announced last week. This diagnosis has prompted scrutiny as his last known prostate-specific antigen (PSA) test was conducted in 2014, over a decade prior. While some health professionals and political figures have questioned the delay in detection given the comprehensive health monitoring typically afforded to presidents, medical experts cited in the report note that discontinuing PSA screening in older patients is not uncommon. Specifically, the U.S. Preventive Services Task Force advised against PSA-based screening for men older than 70 in 2017, a guideline that aligns with the decision to potentially cease or reduce testing for Biden, who was in his early 70s at the time of his last screening. Dr. Scott Eggener, a urologic cancer specialist, affirmed that discontinuing PSA screening at age 72 is considered reasonable. The news also surfaces amidst broader discussions regarding Biden's health transparency during his political career, highlighted by a new book detailing concerns about his acuity during his reelection bid. The overall sentiment remains neutral, with minimal direct market impact anticipated from this health update concerning a former president.

Key Decisions for Investors

• Investors should recognize that this health disclosure regarding a former U.S. President, while significant for public and political discourse, is assessed to have a very low direct impact on financial markets or specific investment instruments.
• Monitor any shifts in public or political dialogue concerning health transparency for public figures, as this could have indirect, longer-term governance implications, though immediate portfolio actions are not indicated by this specific news.
• While the event touches upon themes of healthcare and diagnostics, the provided information does not offer a basis for specific investment actions within the healthcare or biotech sectors without further market-specific catalysts.